Irisin is a myokineexcreted via the activation of specific proteases (EC 3.4) from fibronectin type III domain-containing protein. Irisin stimulates proliferation of β-cell and biosynthesis and secretion of insulin. Augmented circulating irisin has been correlated with reduced IR and improved glucose tolerance.Nevertheless, the role of irisin in type 2 diabetes mellitus (T2DM) is indistinct. Studies have revealed that white adipose tissue (WAT) also secretes irisin and circulating irisin is increased in obese persons. Ourobjectivewas to estimate irisin concentrations in patients with T2DM along with obesity and anorexia nervosa (AN).Nevertheless, under conditions of severely altered body weight such as obesity and anorexia nervosa the regulation of irisin remain to be investigated.This observational parallel-group study was conducted in 120 diabetic womenwith AN(T2DM), 60 obese and 60 non-obesecompared with60 healthy normal weight (NW) controls.Circulating irisin levels have beenquantified in serum samples by ELISA.Anthropometric and body composition were performed.The obese T2DM showed significant higher levels of irisin levels compared to non-obese as well as to the NW controls. Irisin also associated positivelywith body weight, BMI, fat mass, obesity measures and blood pressure levels.In conclusion our study demonstratesthe association betweenirisin levels and obesity in diabetic patients.Irisin is not primarily affected by the presence of anorexia nervosain obese T2DM.